The global rivastigmine transdermal patches market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Rivastigmine patch is used for the treatment of dementia which is associated with mild, moderate, or severe Alzheimer’s disease. Additionally, it is also used to treat mild to moderate dementia associated with Parkinson’s disease. However, these patches do not cure the disease completely. The major factor driving the demand for the rivastigmine transdermal patches is the increasing prevalence of dementia across the globe.
According to Alzheimer’s Disease International, a person develops dementia every 3 seconds across the globe. Additionally, in 2020, there were an estimated over 55 million people living with dementia globally with this number anticipated to double every 20 years, to reach 78 million in 2030 and 139 million in 2050. Moreover, the major increase in the patients with dementia will be in developing countries with 60% of people with dementia living in low and middle-income countries in 2020 which is anticipated to rise to 71% by 2050. Furthermore, there are over 10 million new cases of dementia each year globally which implies one new case every 3.2 seconds. Hence, the increasing prevalence of dementia is driving the demand for rivastigmine transdermal patches which in turn is driving the growth of the market.
To Request a Sample of our Report on Rivastigmine Transdermal Patches Market: https://www.omrglobal.com/request-sample/rivastigmine-transdermal-patches-market
Some major players in the market include Novartis International AG, Ono Pharmaceutical Co., Ltd., and Luye Pharma Group, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in March 2019, Amneal Pharmaceuticals, Inc. announced the launch of its generic version of Exelon Patch (Rivastigmine Transdermal System). It is avaible in 4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
Segment Covered-
- By Type
- By Application
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape- Novartis International AG, Ono Pharmaceutical Co., Ltd., and Luye Pharma Group, among others.
(Get 15% Discount on Buying this Report)
A full Report of Rivastigmine Transdermal Patches Market is Available @ https://www.omrglobal.com/industry-reports/rivastigmine-transdermal-patches-market
Global Rivastigmine Transdermal Patches Market Report by Segment
By Type
- 4.6mg/24hr
- 9.5mg/24hr
- 13.3 mg/24hr
By Application
- Alzheimer’s Disease
- Parkinson
- Other
Global Rivastigmine Transdermal Patches Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
